{"id":"https://openalex.org/W4200217117","doi":"https://doi.org/10.1158/1535-7163.targ-21-p102","title":"Abstract P102: NTX-1088, A potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity","display_name":"Abstract P102: NTX-1088, A potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity","publication_year":2021,"publication_date":"2021-12-01","ids":{"openalex":"https://openalex.org/W4200217117","doi":"https://doi.org/10.1158/1535-7163.targ-21-p102"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-21-p102","doi":"https://doi.org/10.1158/1535-7163.targ-21-p102","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-21-p102","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Pini Tsukerman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pini Tsukerman","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074978291","display_name":"Anas Atieh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anas Atieh","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113150167","display_name":"Akram Obeidat","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Akram Obeidat","raw_affiliation_strings":["1Nectin Therapeutics, Jerusalem, Israel,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Nectin Therapeutics, Jerusalem, Israel,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082520283","display_name":"Keren Paz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Keren Paz","raw_affiliation_strings":["2Nectin Therapeutics, New York, NY,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Nectin Therapeutics, New York, NY,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007968346","display_name":"Guy Cinamon","orcid":"https://orcid.org/0000-0002-6988-1817","observed_orcids":["https://orcid.org/0000-0002-6988-1817"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Guy Cinamon","raw_affiliation_strings":["3Nectin Therapeutics, Tel Aviv, Israel,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Nectin Therapeutics, Tel Aviv, Israel,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064131245","display_name":"Tihana Lenac Rovi\u0161","orcid":"https://orcid.org/0000-0002-3299-1334","observed_orcids":["https://orcid.org/0000-0002-3299-1334"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tihana Lenac Rovi\u0161","raw_affiliation_strings":["4MEDRI, Rijeka, Croatia,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4MEDRI, Rijeka, Croatia,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077303927","display_name":"Lea Hir\u0161l","orcid":"https://orcid.org/0000-0003-1431-8581","observed_orcids":["https://orcid.org/0000-0003-1431-8581"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lea Hirsl","raw_affiliation_strings":["4MEDRI, Rijeka, Croatia,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4MEDRI, Rijeka, Croatia,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044025083","display_name":"Paola Kucan Brilc","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paola Kucan Brilc","raw_affiliation_strings":["4MEDRI, Rijeka, Croatia,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4MEDRI, Rijeka, Croatia,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038051461","display_name":"Stipan Jonji\u0107","orcid":"https://orcid.org/0000-0001-5003-3108","observed_orcids":["https://orcid.org/0000-0001-5003-3108"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stipan Jonjic","raw_affiliation_strings":["4MEDRI, Rijeka, Croatia,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4MEDRI, Rijeka, Croatia,","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5035583924","display_name":"Ofer Mandelboim","orcid":"https://orcid.org/0000-0002-9354-1855","observed_orcids":["https://orcid.org/0000-0002-9354-1855"]},"institutions":[{"id":"https://openalex.org/I197251160","display_name":"Hebrew University of Jerusalem","ror":"https://ror.org/03qxff017","country_code":"IL","type":"education","lineage":["https://openalex.org/I197251160"]}],"countries":["IL"],"is_corresponding":false,"raw_author_name":"Ofer Mandelboim","raw_affiliation_strings":["5HUJI, Jerusalem, Israel"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5HUJI, Jerusalem, Israel","institution_ids":["https://openalex.org/I197251160"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"20","issue":"12_Supplement","first_page":"P102","last_page":"P102"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tigit","display_name":"TIGIT","score":0.7509999871253967},{"id":"https://openalex.org/keywords/cd96","display_name":"CD96","score":0.9660000205039978},{"id":"https://openalex.org/keywords/anti-pd-1-combination-therapy","display_name":"anti-PD-1 combination therapy","score":0.7950000166893005},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.984000027179718},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-resistance","display_name":"immune checkpoint inhibitor resistance","score":0.5189999938011169},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.7609999775886536},{"id":"https://openalex.org/keywords/nk-cell-activation","display_name":"NK cell activation","score":0.7829999923706055},{"id":"https://openalex.org/keywords/cd8-t-cell-activation","display_name":"CD8+ T cell activation","score":0.8709999918937683}],"concepts":[{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.6418753862380981},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6022071242332458},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.5557700395584106},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5376468896865845},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.47154003381729126},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.43982207775115967},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.4314281642436981},{"id":"https://openalex.org/C2779118045","wikidata":"https://www.wikidata.org/wiki/Q21114021","display_name":"TIGIT","level":4,"score":0.41269010305404663},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.31543028354644775}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-21-p102","doi":"https://doi.org/10.1158/1535-7163.targ-21-p102","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-21-p102","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4206777282","https://openalex.org/W4282941334","https://openalex.org/W3213939668","https://openalex.org/W4308377055","https://openalex.org/W4307906976","https://openalex.org/W4393093802","https://openalex.org/W4362545139","https://openalex.org/W7148649001","https://openalex.org/W7162525655","https://openalex.org/W4388074395"],"abstract_inverted_index":{"Abstract":[0],"The":[1,93],"poliovirus":[2],"receptor":[3,132],"(PVR,":[4],"CD155)":[5],"represents":[6],"a":[7,18,80,153,189,238,281,285,345,409],"resistance":[8,43],"mechanism":[9,387],"to":[10,44,55,96,122,244,255,270,288,325,328,363],"approved":[11],"immune":[12,22,26,148,164,176,202,377,414],"checkpoint":[13],"inhibitors":[14],"(ICIs).":[15],"It":[16],"is":[17,79,117,368,399,408],"key":[19],"regulator":[20],"of":[21,33,52,90,139,147,186,217,221,273,290,294,318,323,330,355,372,388,395,405,458,468],"activation,":[23,204,415],"that":[24,289,311,329],"modifies":[25],"function":[27,457],"through":[28,119],"multiple":[29,60],"mechanisms.":[30],"Increased":[31],"levels":[32,326],"PVR":[34,53,64,97,128],"expression":[35,143,455],"on":[36,144,474],"tumor":[37,57,162,222,347,359],"cells":[38,149,178],"have":[39],"been":[40],"associated":[41],"with":[42,75,98,104,174,195,228,265,275,301],"anti-PD-(L)1":[45],"therapy":[46],"in":[47,59,152,183,193,226,252,263,412,421],"clinical":[48],"settings,":[49],"while":[50],"loss":[51],"led":[54],"reduced":[56,320],"growth":[58,348],"pre-clinical":[61],"models.":[62],"Targeting":[63],"using":[65,160],"blocking":[66],"mAbs":[67],"offers":[68],"an":[69],"attractive":[70],"therapeutic":[71],"approach":[72],"for":[73,87,303,381,460],"patients":[74],"advanced":[76],"cancer.":[77],"NTX-1088":[78,115,157,199,230,248,262,279,306,324,340,379],"first-in-class,":[81,451],"potent,":[82],"anti-PVR":[83,452],"mAb":[84,197,246],"being":[85],"developed":[86],"the":[88,124,130,145,184,271,291,308,321,337,369,382,402,422,469],"treatment":[89],"solid":[91],"tumors.":[92],"antibody":[94],"binds":[95],"high":[99],"affinity,":[100],"blocks":[101],"its":[102,120,142,253],"interactions":[103],"TIGIT":[105,295,396],"and":[106,108,129,150,163,192,219,258,296,298,376,392,397,456,477],"CD96,":[107],"thus":[109],"interrupt":[110],"their":[111],"immunosuppressive":[112],"signaling.":[113],"However,":[114],"forte":[116],"manifested":[118],"ability":[121,254],"block":[123],"critical":[125],"interaction":[126],"between":[127],"costimulatory":[131],"DNAM1":[133,314,319,374,459],"(CD226).":[134],"This":[135,367,407],"blockade":[136,293,317,394],"prevents":[137],"internalization":[138],"DNAM1,":[140],"restores":[141,454],"surface":[146],"results":[151],"robust":[154,346],"antitumor":[155,413,463],"activation.":[156,378],"was":[158,267,307],"tested":[159,225,420],"several":[161],"cell":[165,170,203],"co-culture":[166],"systems.":[167],"Various":[168],"cancer":[169],"lines":[171],"were":[172],"co-incubated":[173],"relevant":[175],"effector":[177],"from":[179,210],"healthy":[180],"human":[181],"donors,":[182],"presence":[185],"NTX-1088,":[187,448],"as":[188,205,280],"single":[190,282],"agent":[191,283],"combination":[194,227,264,272],"anti-PD-1":[196],"(pembrolizumab).":[198],"significantly":[200,268,312,352],"increased":[201,232],"measured":[206,234],"by":[207,351,401],"IFNg":[208],"release":[209],"activated":[211],"polyclonal":[212],"CD8+":[213,358],"T":[214,257],"cells,":[215,361],"induction":[216],"CD137":[218],"killing":[220],"cells.":[223,260],"When":[224,242],"pembrolizumab,":[229],"further":[231,299],"all":[233],"activation":[235],"parameters,":[236],"suggesting":[237],"potential":[239],"synergistic":[240],"effect.":[241],"compared":[243,362],"anti-TIGIT":[245,276,331],"(tiragolumab),":[247],"demonstrated":[249],"clear":[250],"superiority":[251],"activate":[256],"NK":[259],"Furthermore,":[261],"pembrolizumab":[266,274],"superior":[269],"mAb.":[277,332],"Interestingly,":[278],"showed":[284],"comparable":[286,327],"effect":[287],"combined":[292],"CD112R,":[297],"synergized":[300],"anti-CD112R":[302],"maximal":[304],"activity.":[305],"only":[309],"intervention":[310],"restored":[313],"levels,":[315],"whereas":[316],"activity":[322],"Humanized":[333],"murine":[334],"models":[335],"confirmed":[336],"above":[338],"observations;":[339],"exhibited":[341],"strong":[342],"efficacy,":[343],"inducing":[344],"inhibition,":[349],"accompanied":[350],"higher":[353],"prevalence":[354],"CD137+,":[356],"DNAM1+,":[357],"infiltrating":[360],"control":[364],"treated":[365],"mice.":[366],"first":[370,383],"report":[371],"drug-induced":[373],"restoration":[375,404],"shows,":[380],"time,":[384],"exclusive":[385],"triple":[386],"action,":[389],"whereby":[390],"simultaneous":[391],"effective":[393],"CD96":[398],"complemented":[400],"efficient":[403],"DNAM1.":[406],"step":[410],"change":[411],"which":[416],"will":[417],"soon":[418],"be":[419],"clinic.":[423],"Citation":[424],"Format:":[425],"Pini":[426],"Tsukerman,":[427],"Anas":[428],"Atieh,":[429],"Akram":[430],"Obeidat,":[431],"Keren":[432],"Paz,":[433],"Guy":[434],"Cinamon,":[435],"Tihana":[436],"Lenac":[437],"Rovi\u0161,":[438],"Lea":[439],"Hirsl,":[440],"Paola":[441],"Kucan":[442],"Brilc,":[443],"Stipan":[444],"Jonjic,":[445],"Ofer":[446],"Mandelboim.":[447],"A":[449],"potent":[450],"mAb,":[453],"optimal":[461],"DNAM1-mediated":[462],"immunity":[464],"[abstract].":[465],"In:":[466],"Proceedings":[467],"AACR-NCI-EORTC":[470],"Virtual":[471],"International":[472],"Conference":[473],"Molecular":[475],"Targets":[476],"Cancer":[478,487],"Therapeutics;":[479],"2021":[480],"Oct":[481],"7-10.":[482],"Philadelphia":[483],"(PA):":[484],"AACR;":[485],"Mol":[486],"Ther":[488],"2021;20(12":[489],"Suppl):Abstract":[490],"nr":[491],"P102.":[492]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2021-12-31T00:00:00"}